Calcium channel blockers inhibit proliferation and matrix production in rat mesangial cells: Possible mechanism of suppression of AP-1 and CREB activities

Nephron

Volumn 85, Issue 1, 2000, Pages 71-80

  Sugiura, Toshihiro ^a   Imai, Enyu ^a   Moriyama, Toshiki ^a   Horio, Masaru ^b   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Activator protein 1; Calcium channel blockers; Cyclic adenosine monophosphate responsive element binding protein; Mesangial cells; Transforming growth factor beta

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; COLLAGEN TYPE 1; CYCLIC AMP BINDING PROTEIN; FIBRONECTIN; NIFEDIPINE; NISOLDIPINE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GLOMERULONEPHRITIS; MESANGIUM CELL; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RAT;

EID: 0034092516     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045633     Document Type: Article

References (38)

1. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981; 241:F85-F93.
2. Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF: Antihypertensive treatment of patients with proteinurie renal diseases: Risks or benefits of calcium channel blockers? Kidney Int 1998;53:1559-1573.
3. Jackson B, Johnston CI: The contribution of systemic hypertension to progression of chronic renal failure in the rat remnant kidney: Effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor. J Hypertens 1988;6:495-501.
4. Brunner FP, Bock HA, Hermle M, Thiel G, Mihatsch MJ: Control of hypertension by verapamil enhances renal damage in a rat remnant kidney model. Nephrol Dial Transplant 1991; 6:420-427.
5. Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD: Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993;43: 808-814.
6. Dworkin LD, Feiner HD, Parker M, Tolbert E: Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 1991;39:1112-1117.
7. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasedelli M, Stallone C, Sanna G, Gaggi R: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992;42:452-458.
8. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-1650.
9. Shultz PJ, Raij L: Inhibition of human mesangial cell proliferation by calcium channel blockers. Hypertension 1990;15(suppl 1):76-80.
10. Fujiwara Y, Ochi S, Izumi M, Yokoyama K, Arai M, Ando A, Nagaoka A, Kamada T, Ueda N: Mesangial cell growth in genetically hypertensive rats and effect of calcium antagonists upon this growth. Blood Press 1992;1(suppl 3): 22-26.
11. Oda H, Yorioka N, Ito T, Yamashita K, Kushihata S, Yamakido M: Nicardipine hydrochloride suppresses DNA synthesis in human mesangial cells stimulated with recombinant human (rh) platelet-derived growth factor AA, rh interleukin-1α, or rh tumor necrosis factor-α. Nephron 1996;73:16-22.
12. 2+ channels. Kidney Int 1996;49:868-879.
13. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, Roberts AB: Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 1990;10:1492-1497.
14. Scotto L, Vaduva PI, Wager RE, Assoian RK: Type beta 1 transforming growth factor gene expression: A corrected mRNA structure reveals a downstream phorbol ester responsive element in human cells. J Biol Chem 1990;265: 2203-2208.
15. 2 activates mitogen-activated protein kinase in cultured rat mesangial cells. FEBS Lett 1995;370:141-145.
16. Ziyadeh FN, Sharma K, Ericksen M, Wolf G: Stimulation of collagen gene expression and protien synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 1994;93:536-542.
17. Qian SW, Kondaiah P, Roberts AB, Sporn MB: cDNA cloning by PCR of rat transforming growth factor-β-1. Nucleic Acids Res 1990;18: 3059.
18. Schwarzbauer JE, Tamkum JW, Lemischka IR, Hynes RO: Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell 1983;35:421-431.
19. Genovese C. Rowe D, Kream B: Construction of DNA sequences complementary to rat alpha1 and alpha2 collagen mRNA and their use in studying the regulation of type I collagen synthesis by 1,25-dihydroxyvitamin D. Biochemistry 1984;23:6210-6216.
20. Sugiura T, Yamauchi A, Kitamura H, Matsuoka Y, Horio M, Imai E, Hori M: Effects of Hypertonic stress on transforming growth factor-β activity in normal rat kidney cells. Kidney Int 1998;53:1654-1660.
21. Sadowski HB, Gilman MZ: Cell-free activation of a DNA-hinding protein by epidermal growth factor. Nature 1993;362:79-83.
22. Ausbel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K: in Current Protocols in Molecular Biology. New York, Wiley & Sons, 1987.
23. Border WA, Okuda S, Languino LR, Ruoslahti E: Transforming growth factor-β regulates production of proteoglycan by mesangial cells. Kidney Int 1990;37:689-695.
24. Okuda S, Languino LR, Ruoslahti E, Border WA: Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 1990;86:453-462.
25. Coimbra T, Wiggins R, Noh JW, Merritt S, Phan SH: Transforming growth factor-β production in anti-glomerular basement membrane disease in the rabbit. Am J Pathol 1991; 138:223-234.
26. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor-β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.
27. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derivd growth factor gene into the rat kidney. J Clin Invest 1993;92: 2597-2601.
28. Karin M, Liu Zg, Zandi E: AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-246.
29. Kreisberg JI, Garoni JA, Radnik R, Ayo SH: High glucose and TGF-β1 stimulate fibronectin gene expression through cAMP response element. Kidney Int 1994;46:1019-1024.
30. 2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996;93:5478-5482.
31. Lei J, Silbige S, Ziyadeh FN, Neugarten J: Serum-stimulated al type IV collagen gene transcription is mediated by TGF-β and inhibited by estradiol. Am J Physiol 1998;274: F252-F258.
32. Chung KY, Agarwal A, Uitto J, Mauviel A: An AP-1 binding sequence is essential for regulation of the human α2(I) collagen (COL1A2) promoter activity by transforming growth factor-β. J Biol Chem 1996;271:3272-3278.
33. Greenwel P, Inagaki Y, Hu W, Walsh M, Ramirez F: Sp1 is required for the early response of α2(I) collagen to transforming growth factor-β1. J Biol Chem 1997;272:19738-19745.
34. Silbiger S, Lei J, Neugarten J: Estradiol suppresses type I collagen synthesis via activation of activator protein-1. Kidney Int 1999;55: 1268-1276.
35. Rauscher FJD, Voulalas PJ, Franza BRJ, Curran T: Fos and Jun hind cooperatively to the AP-1 site: Reconstitution in vitro. Genes Dev 1988;2:1678-1699.
36. Bowlus CL, McQuillan JJ, Dean DC: Characterization of three different elements in the 5′-flanking region of the fibronectin gene which mediate a transcriptional response to cAMP. J Biol Chem 1991;266:1122-1127.
37. Sassone-Corsi P, Ransone LJ, Verma IM: Cross-talk in signal transduction: TPA-inducible factor jun/AP-1 activates cAMP-responsive enhancer elements. Oncogene 1990;5:427-431.
38. Alam R, Kalaoka S, Alam S, Yatsu F: Inhibition of vascular smooth muscle cell proliferation by the calcium antagonist clentiazem: Role of protein kinase C. Atherosclerosis 1996;126: 207-219.